Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.
2. Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2020;47:11–35.
3. Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M. Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a single-center series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25(2):404–13.
4. Arjona-Sánchez Á, Martínez-López A, Valenzuela-Molina F, Rufián-Andújar B, Rufián-Peña S, Casado-Adam Á, et al. A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei. Ann Surg Oncol. 2022;29(1):126–36.
5. Martín Román L, Lozano P, Baratti D, et al. Validation of a nomogram to predict recurrence in patients with mucinous neoplasms of the appendix with peritoneal dissemination after cytoreductive surgery and HIPEC. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12060-8